Actively Recruiting
CINSARC Signature and Correlation With Hemotherapy Efficacy in Soft-tissue Sarcomas. A Biomarker Study.
Led by Institut Bergonié · Updated on 2025-12-02
205
Participants Needed
10
Research Sites
600 weeks
Total Duration
On this page
Sponsors
I
Institut Bergonié
Lead Sponsor
N
National Cancer Institute, France
Collaborating Sponsor
AI-Summary
What this Trial Is About
This is a prospective observational biomarker study including patients with non-metastatic, soft-tissue sarcomas (STS) for whom neoadjuvant chemotherapy is considered as the best option by the multidisciplinary sarcoma team of one of the participating centers.
CONDITIONS
Official Title
CINSARC Signature and Correlation With Hemotherapy Efficacy in Soft-tissue Sarcomas. A Biomarker Study.
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histologically confirmed soft-tissue sarcoma by central review or confirmed by the RRePS Network
- Available archived frozen tumor tissue or patient agrees to a biopsy for research
- Non-metastatic disease where chemotherapy before surgery is expected to improve local control
- Age 18 years or older
- ECOG performance status of 0 or 1
- Measurable disease by RECIST v1.1 outside previously irradiated areas
- Neoadjuvant anthracycline-based chemotherapy recommended by the multidisciplinary sarcoma team
- No other malignant disease diagnosed or treated in the last 2 years except certain in situ carcinomas
- Signed informed consent before study procedures
- Patient has social security coverage as required by French law
You will not qualify if you...
- Diagnosis other than soft-tissue sarcoma
- Specific histological subtypes excluded: well-differentiated liposarcoma, alveolar soft-part sarcoma, dermatofibrosarcoma protuberans, clear-cell sarcoma, rhabdomyosarcoma
- Previous treatment for the sarcoma
- Medical reasons preventing chemotherapy as judged by the investigator
- Participation in another medical or therapeutic study within the last 30 days
- Previous enrollment in this study
- Pregnant or breastfeeding women
- Unable to follow or comply with study procedures due to geographic, social, or psychological reasons
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 10 locations
1
Institut Bergonié
Bordeaux, France, 33076
Actively Recruiting
2
Centre Georges François Leclerc
Dijon, France, 21079
Actively Recruiting
3
Centre Oscar Lambret
Lille, France, 59020
Not Yet Recruiting
4
Centre Léon Bérard
Lyon, France, 69373
Actively Recruiting
5
Institut Paoli Calmettes
Marseille, France, 13273
Actively Recruiting
6
AP-HM _ Hôpital de la Timone
Marseille, France, 13385
Actively Recruiting
7
Institut de Cancérologie de l'Ouest
Nantes, France, 44805
Actively Recruiting
8
Institut Curie
Paris, France, 75005
Not Yet Recruiting
9
Institut Claudius Regaud - IUCT-0
Toulouse, France, 31052
Actively Recruiting
10
Institut Gustave Roussy
Villejuif, France, 94805
Not Yet Recruiting
Research Team
A
Antoine ITALIANO, MD,PhD
CONTACT
S
Simone MATHOULIN-PELISSIER, MD,PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
OTHER
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here